Cardiol Therapeutics Inc.

CRDL on TSXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
2.66CAN -1.48%17,2951.8700 - 5.000087.28M
CRTPF on OTCQXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
2.07US -0.93%11,8181.0800 - 3.830068.827M

Contact Information

Cardiol Therapeutics Inc.

Headquarters:
2265 Upper Middle Road East , Suite 602
Oakville, Ontario
Canada, L6H 0G5
Tel: (289) 910-0850
Email: Send a message
Website: Visit website
For more information...
Lead: Daniel Gordon
Dec 9, 2020 - 1:00 PM PST Corporate Presentation - San Francisco
Dec 15, 2020 - 1:00 PM PST Corporate Presentation - Los Angeles
Jan 19, 2021 - 1:00 PM PST Corporate Presentation - Seattle

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease. The Company recently received approval from the U.S. FDA for its Investigational New Drug (IND) application to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC free (<10 ppm).

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age, and is developing a proprietary subcutaneous cannabidiol formulation for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

While advancing important clinical trials in inflammatory heart disease, Cardiol is generating a near-term revenue opportunity in the growing Canadian medical cannabinoid market – currently exceeding $600 million annually – with its recently launched commercial product, Cortalex™, www.cortalex.com. Cortalex is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Shoppers™ https://cannabis.shoppersdrugmart.ca/.

For further information about Cardiol Therapeutics, please visit cardiolrx.com.

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chief Medical Officer

Chris Waddick, MBA, CPA, CMA - Chief Financial Officer

Thomas Moffatt, BBA - Chief Commercial Officer

Anthony E. Bolton, BSc, PhD, DSc - Director of Research

Andrea B. Parker, MSc, PhD - Director of Clinical Affairs

Anne Tomalin, BA, BSc, RAC - Director of Regulatory Affairs

Blagoja Ristevski, BSc, CHE - Director of Chemical Engineering and Manufacturing

Dolly Kao, BSc, JD - Intellectual Property Counsel

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chairman and Chief Medical Officer

Guillermo Torre-Amione, MD, PhD - Director

Deborah Brown, MBA - Director

Peter Pekos , BSc, MSc - Director

Colin G. Stott, BSc (Hons) - Director

Iain Chalmers, MBA - Director

Stock Information

Events

Dec 9, 2020 - 1:00 PM PST Corporate Presentation - San Francisco
Dec 15, 2020 - 1:00 PM PST Corporate Presentation - Los Angeles
Jan 19, 2021 - 1:00 PM PST Corporate Presentation - Seattle

Company Overview

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease. The Company recently received approval from the U.S. FDA for its Investigational New Drug (IND) application to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC free (<10 ppm).

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age, and is developing a proprietary subcutaneous cannabidiol formulation for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

While advancing important clinical trials in inflammatory heart disease, Cardiol is generating a near-term revenue opportunity in the growing Canadian medical cannabinoid market – currently exceeding $600 million annually – with its recently launched commercial product, Cortalex™, www.cortalex.com. Cortalex is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Shoppers™ https://cannabis.shoppersdrugmart.ca/.

For further information about Cardiol Therapeutics, please visit cardiolrx.com.

Management

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chief Medical Officer

Chris Waddick, MBA, CPA, CMA - Chief Financial Officer

Thomas Moffatt, BBA - Chief Commercial Officer

Anthony E. Bolton, BSc, PhD, DSc - Director of Research

Andrea B. Parker, MSc, PhD - Director of Clinical Affairs

Anne Tomalin, BA, BSc, RAC - Director of Regulatory Affairs

Blagoja Ristevski, BSc, CHE - Director of Chemical Engineering and Manufacturing

Dolly Kao, BSc, JD - Intellectual Property Counsel

Board of Directors

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chairman and Chief Medical Officer

Guillermo Torre-Amione, MD, PhD - Director

Deborah Brown, MBA - Director

Peter Pekos , BSc, MSc - Director

Colin G. Stott, BSc (Hons) - Director

Iain Chalmers, MBA - Director

Contact Information

Headquarters:
2265 Upper Middle Road East , Suite 602
Oakville, Ontario
L6H 0G5, Canada
Telephone: (289) 910-0850
Email: Send a message
Website: Visit website